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HaploinsufﬁciencyDiamond Blackfan anemia is a red cell hypoplasia that typically presentswithin the ﬁrst year of life. Most cases of
Diamond Blackfan anemia are caused by ribosome assembly defects linked to haploinsufﬁciency for structural
proteins of either ribosomal subunit. Nucleolar stress associated with abortive ribosome assembly leads to p53
activation via the interaction of free ribosomal proteins with HDM2, a negative regulator of p53. Signiﬁcant
challenges remain in linking this nucleolar stress signaling pathway to the clinical features of Diamond Blackfan
anemia. Deﬁning aspects of disease presentation may relate to developmental and physiological triggers that
work in conjunction with nucleolar stress signaling to heighten the p53 response in the developing erythron
after birth. The growing number of ribosomopathies provides additional challenges for linking molecular
mechanisms with clinical phenotypes. This article is part of a Special Issue entitled: Role of the Nucleolus in
Human Disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
1.1. The pathophysiology of Diamond Blackfan anemia
Diamond Blackfan anemia (DBA) is a rare hypoplastic macrocytic
anemia that typically presents in the ﬁrst year of life [1]. In addition to
anemia, patients with DBA present with a heterogeneous collection of
congenital anomalies including triphlangeal thumbs, craniofacial anom-
alies, and urogenital and cardiac defects. Individuals with DBA also
have an increased risk for malignancies, particularly myelodysplastic
syndrome [2].
The underlying genetic basis for DBA is known in approximately 65%
of the patient cohort [3]. Of the genes identiﬁed to date, all but one
encode structural proteins of either the 40S or 60S ribosomal subunit.
The exception is the recently discovered GATA1 gene which encodes a
transcription factor involved in erythroid development [4]. Because
the focus of this special issue is on the role of the nucleolus in human
disease, we will focus here on the role of ribosomal proteins in the
pathophysiology of DBA.
To date, 11 genes encoding ribosomal proteins have been implicated
in DBA [3]. In themajority of cases, DBA arises spontaneously by a loss of
function mutation in one of two copies of the ribosomal protein gene.
When familial, the disease is typically transmitted in an autosomal
dominant fashion. Haploinsufﬁciency for each of the known DBA
genes has been shown to affect pre-ribosomal RNA (rRNA) processing
and interfere with the biogenesis of either the 40S or 60S ribosomal
subunit depending on which ribosomal protein is affected [5–7].e Nucleolus in Human Disease.
ights reserved.While it still remains a challenge to envision how haploinsufﬁciency
for a ribosomal protein could give rise to the relatively selective
erythroid defect in DBA, independent studies on 5q− syndrome have
provided compelling support for the relationship between ribosomal
protein haploinsufﬁciency and erythroid maturation. The 5q−
syndrome is a subtype of myelodysplastic syndrome with dysplastic
cells in the bone marrow harboring deletions on the long arm of chro-
mosome 5 [8]. As these clones expand in the bone marrow they fail to
efﬁciently mature along the erythroid lineage resulting in a refractory
anemia. Deletions in 5q include the RPS14 gene and Ebert and
colleagues have shown that subsequent haploinsufﬁciency for RPS14 in-
terferes with erythroid maturation of 5q− clones suggesting that 5q−
syndrome may be considered an acquired form of DBA [9].
Patients with DBA have a hypocellular bone marrow with a notable
absence of erythroid precursors. Early studies revealed that erythroid
precursors from DBA patients had a pro-apoptotic phenotype [10].
More recent studies in a number of different model systems have
demonstrated that this pro-apoptotic phenotype is associated with
elevated levels of p53 [11–15]. Moreover, reduced levels of p53 have
been shown to reverse phenotypes associated with decreased
expression of ribosomal proteins in different model systems suggesting
a critical role for p53 activation in DBA pathophysiology [11,12,15].
2. Abortive ribosome assembly and p53 activation
Numerous lines of investigation have provided a potential mecha-
nismwhereby abortive ribosome assembly could lead to p53 activation.
The incorporation of ribosomal proteins into nascent ribosomal sub-
units occurs through a hierarchical pathway where certain ribosomal
proteins bind directly to rRNA and others assemble later via protein–
protein and protein–RNA interactions [16]. When subunit assembly is
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process is aborted and pre-rRNA degraded [17]. The fate of ribosomal
proteins is less clear with some unassembled proteins being degraded
and others diverted to alternative fates [18].
One such alternative is the interaction of liberated ribosomal pro-
teins with proteins like HDM2 (MDM2 in mice), a critical regulator of
p53 levels [19]. HDM2 is a ubiquitin ligase that recognizes p53 and tar-
gets it for proteosomal degradation. The binding of ribosomal proteins
to HDM2 inhibits its activity leading to increased levels of p53. A num-
ber of different ribosomal proteins have been shown to interact with
HDM2/MDM2 promoting p53 activation. These proteins include Rps7,
Rps14, Rpl5, Rpl11, Rpl23, and Rpl26 [20,21]. The relative importance
of each of these interactions to p53 activation under conditions of nucle-
olar stress induced by abortive ribosome assembly is controversial [22].
Two ribosomal proteins in particular, Rpl5 and Rpl11, appear to be
central regulators of HDM2 activity against p53. These proteins work
as a complex with 5S rRNA, one of the three mature rRNA species of
the 60S ribosomal subunit [23]. Intriguingly, 5S rRNA is transcribed by
RNA polymerase III which sets it apart from the othermature rRNA spe-
cies which are transcribed as part of a polycistronic transcript by RNA
polymerase I [24]. The use of the 5S RNA subcomplex as a nucleolar sig-
naling complex may provide a rational for setting 5S rRNA apart from
the other mature rRNA species. Fumagali and Thomas have argued
that Rpl5 and Rpl11 are critical regulators of MDM2 when ribosome
synthesis is impaired with other ribosomal proteins playing a far less
signiﬁcant role in p53 activation under these conditions [22]. Their stud-
ies reveal that extraribosomal levels of Rpl11 increase through transla-
tional upregulation or via abortive assembly depending on whether
the 40S or 60S subunit is affected, respectively. The concept of rogue ri-
bosomal proteins regulating HDM2/MDM2 as a means for upregulation
of p53 in response to abortive ribosome assembly provides an appealing
model for the underlying molecular basis of DBA [25].
Complicating this model for p53 activation is the ﬁnding that both
RPL5 and RPL11 have been identiﬁed as DBA genes through loss of func-
tion mutations [26]. In these patients either protein becomes limiting
for ribosome assembly leading to pre-rRNA processing defects. It is dif-
ﬁcult to imagine how these proteins could then have critical extra-
ribosomal roles in nucleolar stress signaling under conditions where
they are limiting for subunit assembly. This observation raises the pos-
sibility that ribosomal protein interactions with HDM2 may have a
certain degree of redundancy with other proteins contributing to p53
activation under conditions when Rpl5 or Rpl11 are limiting. That
other proteins may not function in exactly the same manner as Rpl5
and Rpll11 in nucleolar signaling is supported by the ﬁnding that DBA
patients with mutations in RPL5 and RPL11 tend to have more severe
phenotypes with an increased number of congenital anomalies [26].
3. Nucleolar stress and physiological aspects of DBA presentation
While the nucleolar stress model is appealing as a mechanism for
linking abortive ribosome assembly to p53 activation, it does not pro-
vide a ready explanation for the clinical features of DBA patients. DBA
is characterized by a macrocytic anemia that presents in the ﬁrst year
of life, with the mean age of presentation of classical DBA being around
8 weeks [1].While there has been one report of DBA presenting in utero
there is little evidence to suggest that themajority of DBA patients have
complications during fetal erythropoiesis [27]. Thus, there may be a
physiological trigger in the post-natal period that contributes to disease
presentation.
We have previously discussed how a number of factors conspire to
decrease red cell production immediately after birth [1]. After birth
erythropoietin levels decrease in response to higher partial pressures
of oxygen, elevated hemoglobin, and a shift to lower afﬁnity adult
hemoglobin allowing more oxygen delivery to tissues. These effects
lead to a transient anemia until a new steady-state for red cells is
deﬁned. It is worth considering these changes in light of observationsmade in mice defective in MDM2-based regulation of p53 [28]. These
mice were null for MDM2 and had hypomorphic alleles of p53 that
arrest cell division and induce senescence but do not induce apoptosis
[28,29]. MDM2 null mice die during embryogenesis [29]. Tempering
these mice with hypomorphic alleles of p53 allows them to survive
this initial stress but die shortly after birth from hematopoietic failure.
The hematopoietic failure in these mice is linked to elevated reactive
oxygen species (ROS), another stress activator of p53 [28]. Intriguingly,
the hematopoietic defect in cells derived from these mice ex vivo could
be rescued by lowering oxygen partial pressures suggesting that expo-
sure to high atmospheric oxygen at birth could play a role in increasing
ROS and subsequent post-natal deaths. In contrast to thesemice harbor-
ing null alleles of MDM2, a patient with DBA may have reduction in
HDM2 activity via its interaction with ribosomal proteins made avail-
able as a consequence of abortive ribosome assembly. Such a reduction
in HDM2 activity could potentially make patients sensitive to elevated
ROS in the post-natal period. Thus, congenital effects linked to abortive
ribosome assembly and environmental effects linked to enhanced ROS
levels at birth may trigger the hyperactivation of p53 and subsequent
clinical sequelae in DBA patients (Fig. 1).
A concern regarding extrapolating from the MDM2 null mice de-
scribed above to DBA pathophysiology is that in the mouse model the
entire hematopoietic system is affected whereas in classical DBA the ef-
fects are predominantly restricted to the erythroid lineage. It is unclear
from the Abbas manuscript whether all hematopoietic lineages are af-
fected similarly as a consequence of enhanced ROS generation orwheth-
er certain lineagesmay bemore sensitive than others [28]. In this regard
there are reasons to believe that the erythron (tissues producing red
blood cells, red blood cell precursors, and red blood cells) may be
more sensitive to a general increase in ROS, particularly in DBA patients.
Keel et al. have shown that loss of function of FLVCR, a heme transporter
serving as an overﬂowvalue for releasing excess heme from cells, causes
a profound anemia inmice [30]. It has been proposed that uncoupling of
globin synthesis from heme synthesis may occur in cells where ribo-
some synthesis is affected, causing an increased need for FLVCR in elim-
inating excess free heme fromerythroid precursors.While FLVCRhasnot
been directly identiﬁed as a DBA gene there is evidence to suggest that
FLVCR expression may be adversely affected in cells haploinsufﬁcient
for ribosomal proteins [31,32]. Given a role for free heme in ROS produc-
tion [33], dysregulation of FLVCR expression or perturbations in globin
synthesis linked to ribosomal protein haploinsufﬁciency could increase
intracellular heme levels and enhance ROS production in the developing
erythron relative to other hematopoietic lineages.
A related erythroid selectivity may also be evident in p53 activation
in response to abortive ribosome assembly. Dutt et al. have shown a se-
lective effect of ribosomal protein haploinsufﬁciency on p53 activation
in human CD34+ cells induced to differentiate along the erythroid line-
age [13]. Themechanisms underlying this erythroid selectivity however
remain obscure. Thus, an erythroid bias in any of the factors governing
p53 activation in cells haploinsufﬁcient for ribosomal proteins could
tip the scales toward an anemia presentation shortly after birth in the
classical clinical presentation of DBA (Fig. 1).
I have used the term classical in the sense of DBA presenting as a
pure red cell hypoplasia during the ﬁrst year of life. Non-classical
presentations of DBA can include effects on other hematopoietic line-
ages [34]. Such non-classical presentations could potentially be a
consequence of more widespread effects of ROS induction in the
hematopoietic compartment. Other non-classical presentations of DBA
include anemia presenting later in life. In this case, a patientmay some-
how escape the effects of enhanced ROS production on the recovery of
the developing erythron after birth only to succumb later in life as a
consequence of alternative environmental cues. Such non-classical
presentations of DBA are presumably inﬂuenced by one or more
modiﬁer genes which result in phenotypic variation. The same could
also be said for the heterogeneous collection of congenital anomalies
observed in DBA patients.
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Fig. 1. A model for anemia presentation in the post-natal period observed in DBA patients. Environmental cues leading to p53 activation are listed above the dashed line. Potential
contributing factors leading to p53 activation as a consequence of congenital defects arising from ribosomal protein haploinsufﬁciency are shown below the dotted line. In this model,
the combination of congenital, developmental and physiological factors contribute to anemia in the post-natal period.
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DBA is one of a number of bone marrow failures thought to result
from defects in ribosome synthesis [35]. Other bone marrow failures
linked to defects in ribosome synthesis include: dyskeratosis congenita
(DC), cartilage hair hypoplasia (CHH), and Shwachman Diamond
syndrome (SDS). In DC it is now clear that telomerase is the primary
target responsible for disease pathologywith the ribosome also targeted
in the more severe X-linked forms of the disease [36]. Thus for DC, ef-
fects on ribosome synthesis appear to act as a disease modiﬁer. The
same could be said for CHH, although recent studies have raised con-
cerns whether the ribosome is targeted at all in lesions found in the
RMRP gene [37,38]. For SDS, the effect on ribosome synthesis appears
relatively late in the biogenesis pathway and involves a role for the
SBDS protein in recycling eIF-6 from 60S subunits in the cytoplasm
and subsequent effects on the nuclear transport of 60S subunits brought
on by reduced levels of eIF-6 in the nucleus [39,40]. Thus, the mecha-
nisms underlying ribosome maturation defects in SDS appear distinct
from those seen in DBA [41]. These differences may give rise to the dif-
ferent clinical presentations observed in these disease states.
Other potential ribosomopathies lacking a bone marrow failure pre-
sentation include North American Indian Childhood Cirrhosis [42],
Bowen–Conradi Syndrome [43], and Alopecia Neurological Defects
and Endocrinopathy [44]. These latter diseases involve genes encoding
trans-acting factors involved in different steps in ribosome synthesis
that display autosomal recessive transmission inheritance patterns.
The mechanisms linking defects in ribosome synthesis to the clinical
presentations in these disorders are only beginning to emerge.
Any nucleolar-stressmodel for DBA pathophysiologymust ultimate-
ly come to grips with what we have referred to as the Treacher Collins
syndrome (TCS) conundrum. TCS is characterized by craniofacial anom-
alies [45]. Most cases of TCS are caused bymutations in TCOF1, the gene
encoding the nucleolar phosphoprotein Treacle [46]. Treacle has been
shown to inﬂuence transcription by RNA polymerase I and subsequent
methylation of the Pol I transcript [47]. Support for Pol I transcription
as the target underlying TCS pathology comes from the identiﬁcation
of two new TCS genes, POLR1C and POLR1D, which encode shared
subunits of RNA polymerase I and RNA polymerase III [48]. Mutations
in TCOF1 have been shown to affect the proliferation of neural crest
cells during early development and give rise to the characteristic
cranioskeletal hypoplasia observed in afﬂicted individuals and animal
models [49]. Like DBAmodels, aspects of the TCS phenotype can be res-
cued by mutations in p53, indicating a role for the tumor suppressor in
disease pathophysiology. Intriguingly,much of the earlywork on the in-
teraction of ribosomal proteins with MDM2 was carried out using RNA
polymerase I inhibitors to generate free ribosomal proteins with morerecentwork being carried out using knockdownsof the catalytic subunit
of Pol I [50,51]. Thus it seems reasonable to infer that abortive ribosome
assembly linked to a reduction in Pol I transcription through mutations
in TCOF1, POLR1C or POLR1D could liberate ribosomal proteins for inter-
actionswithHDM2/MDM2 in amanner similar to that occurring in DBA.
If so, one would predict a signiﬁcant phenotypic overlap between DBA
and TCS.
While there is some phenotypic overlap betweenDBA andTCS, espe-
cially for DBA patients with mutations in RPL5, the deﬁning characteris-
tic of DBA, anemia, is not observed in TCS patients [26]. Thus, the
exquisite sensitivity of the developing erythron to abortive ribosome as-
sembly linked to defects in genes encoding ribosomal proteins is not ob-
served in patients where defective Pol I transcription appears to be
the primary driver for abortive ribosome assembly. This conundrum
reveals signiﬁcant gaps in our understanding of the role of nucleolar
stress in human diseases linked to failures in ribosome synthesis. The
growing interest in this area as evident throughout this volume provides
optimism that these gaps will be ﬁlled in the not too distant future.
5. Summary
Considerable progress has beenmade over the last few years linking
abortive ribosome assembly to p53 activation as a mechanistic basis
underlying certain ribosomopathies. Challenges remain in understand-
ing the importance of different ribosomal proteins in signaling to p53
activation through interactions with HDM2, although clearly the Rpl5/
Rpl11/5S RNA subcomplex appears to stand out in this regard. Perhaps
the most signiﬁcant challenge to the ﬁeld is in understanding the rela-
tionship between biochemicalmechanisms underlying disease patholo-
gy and aspects of disease presentation. Given the myriad of pathways
that signal to p53 activation, disease presentation may represent an
amalgam of congenital, developmental, and physiological factors that
trigger p53-dependent effector pathways in tissue speciﬁc manners
depending on the genes involved and manners in which ribosome
synthesis is affected.
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